This might pose a problem when using recombinant C1-INH for complement mediated diseases such as ischemia–reperfusion injury, acute myocardial infarction, autoimmune hemolytic anemia and renal transplantation (175–178). Here, SERPING1 is linked to acute myocardial infarction.